# A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

> **NCT05226507** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Nuvectis Pharma, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Advanced Solid Tumor
- Ovarian Cancer
- Ovarian Clear Cell Carcinoma
- Ovarian Clear Cell Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Endometrioid Tumor
- ARID1A Gene Mutation

## Interventions

- **DRUG:** NXP800

## Key facts

- **NCT ID:** NCT05226507
- **Lead sponsor:** Nuvectis Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-31
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05226507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05226507, "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05226507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*